ICS in COPD: Are We Finally Ready to Tailor Treatment?
"New insights suggest personalized approaches to inhaled corticosteroid (ICS) use in COPD could improve outcomes and minimize risks."
For over half a century, inhaled corticosteroids (ICS) have been a mainstay in managing chronic obstructive pulmonary disease (COPD). With decades of research and numerous large-scale trials involving over 40,000 patients, the role of ICS in COPD treatment has been a subject of ongoing debate. While ICS can reduce the risk of exacerbations, their benefits are modest, and they carry potential risks, most notably an increased risk of pneumonia.
The combination of ICS with a long-acting β2-agonist (LABA) has shown promise in improving symptoms and reducing exacerbations compared to either drug alone. However, questions remain about whether this combination is superior to long-acting muscarinic antagonists (LAMA) alone or in combination with LABA (i.e., LABA/LAMA). Current Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines offer various options for symptomatic COPD patients with frequent exacerbations, leaving clinicians to navigate choices like LAMA, LABA/LAMA, ICS/LABA, or even ICS/LABA/LAMA combinations.
This ambiguity often leads to therapeutic decisions based on personal preference or habit rather than solid evidence. Experts have criticized this approach, calling for a shift towards "precision medicine" in COPD management. Now, emerging research is shedding light on how to target ICS therapy to the right patients at the right time, potentially optimizing benefits while minimizing harm.
COPD and Airflow Limitation
COPD is a group of diseases that causes airflow blockage and breathing-related problems, with emphysema and chronic bronchitis identified as the most common types. The CDC reports that smoking is the main cause of COPD, while the Mayo Clinic describes lung damage, airway inflammation, and swelling that limit airflow into and out of the lungs. Cleveland Clinic characterizes the resulting lung and airway damage as irreversible, highlighting a fundamental limitation of treatment: management addresses obstruction and symptoms but cannot simply reverse the underlying damage.
The Origins of ICS in COPD
Inhaled corticosteroids, or ICS, were first discovered 50 years ago, according to the review “Inhaled corticosteroids in COPD: the final verdict is…”. The same source reports that ICS are now the most widely used controller medication in the world for chronic obstructive pulmonary disease. This history helps explain why ICS became central to discussions about COPD treatment, even as their role continues to be evaluated.
Who Benefits Most from ICS in COPD? Asthma History and Eosinophil Counts
Recent studies highlighted in the European Respiratory Journal (ERJ) suggest that ICS should primarily be prescribed to COPD patients with a history of asthma or features indicative of asthma-COPD overlap. As noted by Suissa and Ariel, the inclusion or exclusion of asthma-COPD overlap patients in clinical trials may explain inconsistencies in the outcomes of ICS-containing therapies. Trials like IMPACT and TRIBUTE, which included patients with a prior history of asthma, demonstrated reduced exacerbation rates with ICS-containing combinations.
- Asthma-COPD Overlap: Patients with features of both asthma and COPD tend to respond well to ICS.
- Eosinophil Count: Individuals with higher eosinophil counts (≥300 cells per μL) are more likely to benefit from ICS.
- Withdrawal Considerations: Abruptly stopping ICS can lead to a temporary increase in exacerbations.
Asthma Characteristics and ICS Use
A study of patients in a Dutch well-established asthma/COPD service for primary care examines the prevalence of asthma characteristics in people with COPD. Its summary states that international guidelines recommend prescribing ICS to COPD patients who comply with one of three specified patient characteristics. The available source material does not identify those three characteristics, so the finding supports a criteria-based approach without establishing which individual features should guide treatment.
Personalizing COPD Treatment: A Path Forward
While these findings offer valuable insights, many questions regarding the role of ICS in COPD management remain. Future studies should rigorously test whether newer-generation ICS-based therapies, delivered via ultrafine devices, may prolong survival, particularly in patients with comorbidities. Additionally, the effects of ICS-based therapy on hospitalizations, a major driver of direct costs for COPD care, warrant further investigation. As research progresses, a deeper understanding of COPD pathogenesis and the identification of novel therapeutic targets will pave the way for precision medicine approaches that improve outcomes and quality of life for millions affected by this chronic respiratory condition.
A Broader View of COPD
The COPD Foundation describes COPD as including lung conditions such as emphysema and chronic bronchitis. It notes that COPD can cause shortness of breath, fatigue, and a persistent cough, and is often linked to lung irritants such as smoke and pollution. The foundation also reports that COPD is sometimes genetic, pointing toward a future outlook that must account for varied causes and patient experiences rather than treating the condition as uniform.